Search

Displaying results 2021 - 2030 of 7452 in total
  1. Drug

    Linzagolix

    go.drugbank.com/drugs/DB17083
    ApprovedInvestigational

    [A253667] Linzagolix was approved for use in the European Union in June 2022 for the management of symptoms caused by uterine fibroids.[L43627] … It has been studied for the treatment of estrogen-dependent conditions such as uterine fibroids and endometriosis.

  2. Drug

    Mebeverine

    go.drugbank.com/drugs/DB12554
    ApprovedInvestigationalWithdrawn

    Mebeverine has been investigated for the treatment of Irritable Bowel Syndrome and Post-cholecystectomy Gastrointestinal Spasms.

    Categories: Drugs for Functional Gastrointestinal Disorders
  3. Drug

    Lithium cation

    go.drugbank.com/drugs/DB01356
    ApprovedInvestigationalWithdrawn

    It is also sometimes prescribed as a preventive treatment for migraine disease and cluster headaches.

  4. Drug

    Bacillus calmette-guerin substrain connaught live antigen

    go.drugbank.com/drugs/DB10804
    ApprovedInvestigationalWithdrawn

    Bacillus calmette-guerin substrain connaught live antigen is intravesically administered for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary … or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR).

  5. Drug

    Mumps virus strain B level jeryl lynn live antigen

    go.drugbank.com/drugs/DB10316
    ApprovedInvestigational

    Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease.

    Mixtures: Sterile Diluent for M-M-R II
  6. Drug

    Selpercatinib

    go.drugbank.com/drugs/DB15685
    ApprovedInvestigational

    Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. … Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.

  7. Drug

    Sutilain

    go.drugbank.com/drugs/DB09379
    ApprovedWithdrawn

    It is able to dissolve the intercellular matrix which helps with desquamation.

  8. Drug

    Rimonabant

    go.drugbank.com/drugs/DB06155
    ApprovedWithdrawn

    It was rejected for approval for use in the United States. … It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite.

  9. Drug

    Leniolisib

    go.drugbank.com/drugs/DB16217
    ApprovedInvestigational

    [L45753] Investigations for using leniolisib in primary Sjögren’s syndrome are ongoing.[A258468] … The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).

  10. Drug

    Bromodiphenhydramine

    go.drugbank.com/drugs/DB01237
    Approved

    Bromodiphenhydramine is an ethanolamine antihistamine with antimicrobial property. Bromodiphenhydramine is used in the control of cutaneous allergies. Ethanolamine antihistamines produce marked sedation in most patients.

    Categories: Antihistamines for Systemic Use